Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sang-In Kim

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Oncoimmunology|March 12, 2020
Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer modelShyambabu Chaurasiya, Annie Yang, Seonah Kang, et al.
Molecular Therapy. Oncology|July 13, 2026
Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasisZhifang Zhang, Annie Yang, Anthony K Park, et al.
Molecular Therapy Oncolytics|July 11, 2018
A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell InfectionMichael P O'Leary, Susanne G Warner, Sang-In Kim, et al.
Journal of Translational Medicine|April 28, 2018
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low doseMichael P O'Leary, Audrey H Choi, Sang-In Kim, et al.
Molecular Cancer Therapeutics|December 2, 2020
Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral ImmunitySang-In Kim, Anthony K Park, Shyambabu Chaurasiya, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 24, 2025
Oncolytic Virotherapy in Solid Tumors: A Current ReviewCourtney Chen, Jennifer Cillis, Supriya Deshpande, et al.
Journal for Immunotherapy of Cancer|April 1, 2026
Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memoryAnnie Yang, Zhifang Zhang, Anthony K Park, et al.
Cancer Gene Therapy|June 10, 2021
CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapyZhifang Zhang, Annie Yang, Shyambabu Chaurasiya, et al.
Science Translational Medicine|September 4, 2020
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumorsAnthony K Park, Yuman Fong, Sang-In Kim, et al.
Molecular Therapy Oncolytics|March 23, 2022
Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancerSang-In Kim, Shyambabu Chaurasiya, Venkatesh Sivanandam, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Oncoimmunology|March 12, 2020
Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer modelShyambabu Chaurasiya, Annie Yang, Seonah Kang, et al.
Molecular Therapy. Oncology|July 13, 2026
Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasisZhifang Zhang, Annie Yang, Anthony K Park, et al.
Molecular Therapy Oncolytics|July 11, 2018
A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell InfectionMichael P O'Leary, Susanne G Warner, Sang-In Kim, et al.
Journal of Translational Medicine|April 28, 2018
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low doseMichael P O'Leary, Audrey H Choi, Sang-In Kim, et al.
Molecular Cancer Therapeutics|December 2, 2020
Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral ImmunitySang-In Kim, Anthony K Park, Shyambabu Chaurasiya, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 24, 2025
Oncolytic Virotherapy in Solid Tumors: A Current ReviewCourtney Chen, Jennifer Cillis, Supriya Deshpande, et al.
Journal for Immunotherapy of Cancer|April 1, 2026
Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memoryAnnie Yang, Zhifang Zhang, Anthony K Park, et al.
Cancer Gene Therapy|June 10, 2021
CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapyZhifang Zhang, Annie Yang, Shyambabu Chaurasiya, et al.
Science Translational Medicine|September 4, 2020
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumorsAnthony K Park, Yuman Fong, Sang-In Kim, et al.
Molecular Therapy Oncolytics|March 23, 2022
Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancerSang-In Kim, Shyambabu Chaurasiya, Venkatesh Sivanandam, et al.
Pageof 7